Datadog, D.R. Horton, Sanmina, Alteryx, Planet Fitness, and More Stock Market Movers

Uber Technologies
(UBER) reported its second-ever operating profit in the third quarter, but revenue of $9.3 billion missed analysts’ estimates of $9.5 billion. The company also reported third-quarter gross bookings of $35.3 billion, above Wall Street estimates of $34.6 billion and an increase of 21% from $29.1 billion a year earlier. The stock was up 0.4%.

D.R. Horton
(DHI), the largest publicly traded home builder in the U.S., reported fiscal fourth-quarter earnings of $4.45 a share on revenue of $10.5 billion. Analysts had expected the company to report earnings of $3.94 a share on revenue of $10 billion.
D.R. Horton
also raised its quarterly dividend to 30 cents a share from 25 cents. The stock was up 2.8%.

Sanmina
(SANM) was down 14% after the electronics manufacturing company said it expects fiscal first-quarter adjusted profit of $1.20 to $1.30 a share, below analysts’ estimates of $1.52, and revenue of $1.85 billion to $1.95 billion, below estimates of $2.19 billion.

Alteryx
(AYX) was rising 23% after the software company reported a narrower-than-expected third-quarter loss and sales of $232 million that beat analysts’ estimates. 

Air Products & Chemicals
(APD) was down 11% after fiscal fourth-quarter revenue of $3.19 billion at the industrial gases company missed analysts’ consensus of $3.35 billion.

DigitalOcean
(DOCN) was up 13% after the maker of software for cloud-computing applications was double-upgraded to Buy from Sell at
Goldman Sachs.

Tripadvisor
(TRIP) rose 5.4% after the online travel platform reported adjusted earnings and sales in the third quarter that beat Wall Street expectations. Sales of $533 million rose 16% from a year earlier.

Vertex Pharmaceuticals
(VRTX) reported third-quarter adjusted earnings of $4.08 a share, topping Wall Street expectations of $3.92. Revenue rose 6% to $2.48 billion but just missed forecasts. Vertex said the revenue gains primarily were driven by the “continued performance” of its cystic fibrosis drug Trikafta in the U.S. Vertex raised its full-year guidance for cystic-fibrosis product revenue to $9.85 billion, versus prior guidance of $9.7 billion to $9.8 billion. The stock declined 1.2%.

Third-quarter earnings and revenue at
Planet Fitness
(PLNT) beat analysts’ expectations while same-store sales in the period matched expectations. The stock rose 13%.

GlobalFoundries
(GFS) was up 7.8% after the the contract chip manufacturer’s third-quarter earnings topped analysts’ expectations.

Write to Joe Woelfel at [email protected]